Discover real-time Amgen Inc. Common Stock (AMGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
We take the underlying stock price, the break even point (target price), the days to expiration, and the 52-week historical volatility, and then use those figures in this formula. Depending on the strategy, we use the above or below probability (i.e., the probability the price crosses th...
1/244/247/2410/241/251/26$181$237$293$349$405Closing price on 01/16/25: $269.43High$405.00Average$314.91Low$195.00 Current Consensus isHold The current consensus among 27 investment analysts is to hold stock in Amgen. This rating has held steady since September 2024, when it changed from ...
On rare occasions, our expert team of analysts issues a“Double Down” stockrecommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themse...
Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural di...
THOUSAND OAKS, Calif.,Aug. 6, 2024/PRNewswire/ --Amgen(NASDAQ: AMGN) today announced financial results for the second quarter 2024. "With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver att...
matus kubala, cfa 417 follower s follow summary margins are at record highs thanks to higher efficiency. management has a solid track record of delivering value to shareholders. dcf valuation shows 25-50% upside, stock trading at historically low valuation multiples. basic information price: 153.08...
s stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen’s products that implicate an entire class of products...
Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children...